Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for cardiac light-chain amyloidosis (autophagy/lysosome modulation)
ChiCTR2100052345Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in cardiac amyloidosis comparing Dapagliflozin group with Placebo group (2 arms). Primary endpoints: Interventricular septum thickness and NT-proBNP. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on ChiCTR2100052345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052345.